MNM Bioscience received $800 000 funding through Eureka Eurostars for our newest project

MNM Bioscience began as a bioinformatics company that curates data and then builds artificial intelligence-based algorithms, but it is now looking to branch out into oncology drug target discovery.

With entire genomes at hand, scientists can pinpoint DNA fragments responsible for different cancers and predict patient responses to cancer treatments. However, the sheer volume of whole-genome data makes it difficult to encode the characteristics of genomic variants as features for machine learning algorithms.

Maciej Piernik presented one of our core algorithms at the European Conference on Machine Learning and Principles and Practice of Knowledge Discovery in Databases.

We are thrilled to announce that MNM Bioscience received $800 000 funding through Eureka Eurostars for our newest project.